Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M21,787Revenue (TTM) $M11,077Net Margin (%)4.3Altman Z-Score1.2
Enterprise Value $M36,183EPS (TTM) $0.9Operating Margin %6.3Piotroski F-Score3
P/E(ttm)43.8Beneish M-Score-2.5Pre-tax Margin (%)1.1Higher ROA y-yN
Price/Book2.010-y EBITDA Growth Rate %9.6Quick Ratio1.0Cash flow > EarningsY
Price/Sales1.95-y EBITDA Growth Rate %4.2Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow16.4y-y EBITDA Growth Rate %-12.3ROA % (ttm)1.7Higher Current Ratio y-yN
Dividend Yield %--PEG10.6ROE % (ttm)4.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M536ROIC % (ttm)4.7Gross Margin Increase y-yN

Gurus Latest Trades with MYL

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MYL is held by these investors:



MYL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BRESCH HEATHER MCEO 2016-08-09Sell100,200$50-16.82view
MAROON JOSEPH C MDDirector 2016-06-03Buy1,670$44.95-7.47view
MAROON JOSEPH C MDDirector 2016-05-25Buy2,370$42.47-2.07view
Cindrich Robert JDirector 2016-05-25Buy1,190$42.47-2.07view
HIGGINS MELINA EDirector 2016-05-12Buy19,900$38.687.52view
HIGGINS MELINA EDirector 2016-05-06Buy100$38.697.5view
HIGGINS MELINA EDirector 2016-04-28Buy35,000$42.92-3.1view
COURY ROBERT JExecutive Chairman 2016-04-05Sell217,755$45.96-9.51view
MAROON JOSEPH C MDDirector 2016-03-31Buy4,337$46.36-10.29view
PARRISH MARK WDirector 2016-03-17Buy1,705$44-5.48view

Press Releases about MYL :

Quarterly/Annual Reports about MYL:

News about MYL:

Articles On GuruFocus.com
Companies Aiming for the Billion-Dollar Opioid Addiction Market Mar 18 2017 
America’s War on Drugs Mar 07 2017 
Drug Addiction Treatment Stocks to Watch Feb 22 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
John Paulson's Bargain Stock Jan 30 2017 
Abbott Laboratories: An Undervalued Diamond in Overvalued Markets Jan 24 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Weak Outlook on Mylan Nov 18 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 

More From Other Websites
Mylan Stock Dips On Recall Of 81,000 EpiPens Outside U.S. Mar 23 2017
Apple to make iPhones in India, Mylan recalls EpiPens overseas, Amazon eyes Middle East retail site Mar 23 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
Markets eye critical health bill vote Mar 23 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
Mylan recalls 81K EpiPens outside US Mar 22 2017
Mylan recalls 81,000 EpiPens outside U.S. after reports of failure Mar 22 2017
UPDATE 1-Mylan recalls 81,000 EpiPens outside U.S. after reports of failure Mar 22 2017
Mylan recalls some EpiPens outside U.S. after reports of failure Mar 22 2017
Mylan Receives Tentative Approval from FDA for HIV Therapy Mar 21 2017
Is Mylan N.V. (MYL) a Great Stock for Value Investors? Mar 21 2017
Mylan’s AIDS Drug Combo Secures Tentative FDA Approval Mar 21 2017
Mylan's Government Connections Go Deeper Than Initially Reported Mar 20 2017
Mylan Receives Tentative Approval for "TLE400" Under PEPFAR Mar 20 2017
5 Biotech Companies To Watch In 2017 Mar 17 2017
5 Biotech Companies Set for Major Breakouts In 2017 Mar 17 2017
Improved margins and Advair hopes lift drugmaker Hikma Mar 15 2017
Improved margins and Advair hopes lift drugmaker Hikma Mar 15 2017
Mylan Settles With Genentech Over Patents for Breast Cancer Drug Mar 13 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)